Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil

@article{Yamada2003PlasmaCO,
  title={Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil},
  author={Y. Yamada and T. Hamaguchi and M. Goto and K. Muro and Y. Matsumura and Y. Shimada and K. Shirao and S. Nagayama},
  journal={British Journal of Cancer},
  year={2003},
  volume={89},
  pages={816 - 820}
}
  • Y. Yamada, T. Hamaguchi, +5 authors S. Nagayama
  • Published 2003
  • Medicine
  • British Journal of Cancer
  • The pharmacokinetics and pharmacodynamics of oral S-1, a dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine, were compared with those of protracted venous infusion (PVI) of 5-fluorouracil (5-FU). In all, 10 patients with gastric cancer received PVI of 5-FU at a dose of 250 mg m−2 day−1 for 5 days. After a washout period of 9 days, the patients received two divided doses daily for 28 days. S-1 was administered orally at about 0900 and 1900 hours. The daily dose of S-1 in terms of… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 37 REFERENCES
    Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
    140
    Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
    250